Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.51 |
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 7/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942607 | 0.91 | JAK2 (0.59) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL24852608 | 0.91 | JAK2 (0.59) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL22114894 | 0.91 | JAK2 (0.51) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL30172431 | 0.91 | JAK2 (0.51) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL22114893 | 0.89 | JAK3 (0.52) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL24852446 | 0.89 | JAK3 (0.52) | JAK3JAK2PTK2TNK2IGF1R | |
| SCHEMBL27059971 | 0.85 | JAK2 (0.57) | JAK3JAK2PTK2JAK1IGF1R | |
| SCHEMBL22089671 | 0.84 | JAK3 (0.48) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL29941953 | 0.84 | JAK3 (0.48) | JAK3JAK2PTK2JAK1TNK2 | |
| SCHEMBL27059227 | 0.83 | GPR119 (0.51) | JAK3JAK2PTK2TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885PTK2 1945/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885PTK2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.